Co-sponsored Symposium

Co-sponsored Symposium 1
To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

Thu. May 23, 2024 3:45 PM - 5:45 PM Room 1 (Hall C)

Chair: Koichiro Watanabe (Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan), Nakao Iwata (Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan)

Co-sponsored by Otsuka Pharmaceutical Co., Ltd.

+Add all to schedule

[CSS1-1] The Significance of Personal Goals in Schizophrenia Treatment: Unmet Needs, Therapeutic Approaches, and Recovery Strategies

*Christoph U Correll^1,2 (1. Psychiatry and Molecular Medicine Zucker School of Medicine at Hofstra/Northwell, New York, USA, 2. Department of Child and Adolescent Psychiatry Charité University Medicine, Berlin, Germany)

[CSS1-2] Optimizing Antipsychotic Treatment for Relapse Prevention and Clinical Recovery in Schizophrenia

*Hiroyoshi Takeuchi¹ (1. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan)

[CSS1-3] Psychosocial Treatment with a Focus on Recovery

*Naoki Hashimoto¹ (1. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Japan)

Co-sponsored Symposium

Co-sponsored Symposium 2
Strategic Approaches to Achieve Recovery

Fri. May 24, 2024 10:45 AM - 12:00 PM Room 12 (Hall D5)

Chair: Hiroyuki Uchida (Department of Neuropsychiatry, Keio University School of Medicine)

Co-sponsored by Takeda Pharmaceutical Company Limited, Japan Medical Office/Lundbeck Japan K.K., Medical Affairs

+Add all to schedule

[CSS2-1] Measurement-Based Care in Major Depressive Disorder ~From Remission to Functional Recovery~

*Yoshikazu Takaesu¹ (1. Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus)

[CSS2-2] Challenges to Treatment and Assessment for Achieving Personal Recovery in Patients with Major Depressive Disorder

*Takashi Tsuboi¹ (1. Department of Neuropsychiatry, Kyorin University School of Medicine)

Co-sponsored Symposium

Co-sponsored Symposium 3
Cognitive Impairment is a Core Feature of Schizophrenia

Fri. May 24, 2024 3:00 PM - 4:00 PM Room 2 (Hall B7 (1))

Chair: Philip Harvey (Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine), Kazuyuki Nakagome (National Center of Neurology and Psychiatry)

Co-sponsored by Boehringer Ingelheim International GmbH

[CSS3] Cognitive Impairment Is a Core Feature of Schizophrenia

*Boehringer Ingelheim International GmbH

Co-sponsored Symposium

Co-sponsored Symposium 4
Tobacco Harm Reduction - an Update

Fri. May 24, 2024 5:00 PM - 7:00 PM Room 16 (G502)

Chair: Raymond S Niaura (New York University), Koji Takada (Department of Psyshiatry, Jikei University School of Medicine/Department of Psychology, Teikyo University)
Discussant: Naoyuki Hironaka (Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science)

Co-sponsored by Progressive Policy Institute

+Add all to schedule

[CSS4-1] Harm reduction – origins, successes and untapped potential

*Katarzyna Kinga Kowalczyk¹ (1. Global Public Health Network)

[CSS4-2] Smoking, safer nicotine products and tobacco harm reduction―around the world in fifteen minutes

*David MacKintosh¹ (1. Knowledge•Action•Change)

[CSS4-3] Japan tops the world in reducing cigarette sales

*David T Sweanor^1,2,3 (1. Centre for Health Law, Policy & Ethics, University of Ottawa, 2. Faculty of Law, University of Ottawa, 3. Global Leadership Council, Boston University School of Public Health)

[CSS4-4] Can e-cigarettes help tobacco cigarette smokers quit? A review of the evidence

*Raymond Niaura¹ (1. Departments of Social and Behavioral Sciences, Epidemiology/Department of Epidemiology, School of Global Public Health New York University)

[CSS4-5] Decision-making and habit: understanding maladaptive behaviour from basic animal learning research

*Yutaka Kosaki¹ (1. Department of Psychology, Waseda University)

Co-sponsored Symposium

Co-sponsored Symposium 5
Which interventions are key to change the trajectory of schizophrenia?

Sat. May 25, 2024 2:30 PM - 3:30 PM Room 1 (Hall C)

Chair: Hiroyuki Uchida (Department of Neuropsychiatry, Keio University School of Medicine)

Co-sponsored by Sumitomo Pharma Co.,Ltd. Medical Science

[CSS5] The relevance of nonpsychotic symptoms in the management of schizophrenia

*W. Wolfgang Fleischhacker¹ (1. Medical University Innsbruck)

Co-sponsored Symposium

Co-sponsored Symposium 6
Measurement Based Care in depression

Sat. May 25, 2024 3:50 PM - 5:50 PM Room 14 (G602)

Chair: Masaki Kato (Department of Neuropsychiatry, Kansai Medical University ), Koichiro Watanabe(Department of Neuropsychiatry, Kyorin University School of Medicine)

Co-sponsored by Otsuka Pharmaceutical Co., Ltd. Medical Affairs

+Add all to schedule

[CSS6-1] Measurement Based Care in the Treatment of Depression: Psychotherapeutic Approach to Personal Recovery

*Toshiaki Kikuchi¹ (1. Keio University School of Medicine, Department of Neuropsychiatry)

[CSS6-2] Evaluation of workers with depression at the time of return to work

*Hikaru Hori¹ (1. Department of Psychiatry, Faculty of Medicine, Fukuoka University )

[CSS6-3] About the real Measurement Based Care using IT devices at psychiatric clinic with using the H-SDS & H-SAS

*Seiji Hongo¹ (1. Ichigaya Himorogi Clinic, Nanko Kokoro no Clinic)

Co-sponsored Symposium

Co-sponsored Symposium 7
Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

Sat. May 25, 2024 3:50 PM - 5:50 PM Room 15 (G610)

Chair: Hisatsugu Miyata (Department of Psychiatry, Jikei University School of Medicine/Hirakawa Hospital), Naoyuki Hironaka (Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science)

Co-sponsored by Smoking Research Foundation

+Add all to schedule

[CSS7-1] Development of an animal model to analyze neural mechanisms of behavioral addiction

*Masabumi Minami¹ (1. Dept Pharmacolgy, Faculty of Pharmaceutical Sciences, Hokkaido University)

[CSS7-2] Analysis of addiction using dopamine-related gene-altered mice

*Soichiro Ide¹, Kazutaka Ikeda¹ (1. Addictive Substance Project, Tokyo Metropolitan Institute of Medical Science)

[CSS7-3] Role of basolateral amygdala in formation of preference to nicotine intake behavior

*Atsumi Nitta¹ (1. Department of Pharmaceutical Therapy & Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama)

[CSS7-4] Smoking Behaviors: Factors and Mechanisms Mediating Transition to Addiction

*Kohji Takada^1,2, Yuji Takano³, Naoyuki Hironaka⁴ (1. Department of Psychiatry, Jikei University, 2. Department of Psychology, Teikyo University, 3. Department of Psychological Science, University of Human Environments, 4. Substance Dependence Project, Tokyo Metropolitan Institute of Medical Science )

[CSS7-5] An attempt to create new diagnostic criteria integrating substance dependence and behavioral addiction

*Hisatsugu Miyata^1,2, Risa Yamada³, Atsushi Shimotomai⁴ (1. Department of Psychiatry, Jikei University School of Medicine, 2. Hirakawa Hospital, 3. National Center of Neurology and Psychiatry, 4. Department of Psychology, School of Human Science, Senshu University)

Co-sponsored Symposium

Co-sponsored Symposium 8
The unmet needs of schizophrenia from various stakeholders' point of view　

Sun. May 26, 2024 2:20 PM - 3:50 PM Room 12 (Hall D5)

Chair: Takahiro Nemoto (Department of Neuropsychiatry, Toho University School of Medicine), Satoru Ikezawa( International University of Health and Welfare, IUHW Mita Hospital)

Co-sponsored by Medicine Division, Nippon Boehringer Ingelheim Co., Ltd.

+Add all to schedule

[CSS8-1] 統合失調症当事者へのインタビュー（動画）

*山田悠平¹ (1. 一般社団法人精神障害当事者会ポルケ)

[CSS8-2] Issues for the recovery of patients with schizophrenia
~Employment support facility's point of view~

*Daisuke Haga¹ (1. job training institution ONE MORE TOYONAKA/SENRICHUO)

[CSS8-3] 統合失調症当事者のご家族へのインタビュー（動画）

*岡田久実子¹ (1. 公益社団法人全国精神保健福祉会連合会)

[CSS8-4] After overcoming the acute phase of schizophrenia
~Psychitrist's point of view~

*Hikaru Hori¹ (1. Faculty of medicine, Department of Psychiatry, Fukuoka University)

Co-sponsored Symposium

Co-sponsored Symposium 9
The importance of personalizing long-acting injectables and shared decision-making in schizophrenia

Sun. May 26, 2024 2:50 PM - 3:50 PM Room 1 (Hall C)

Chair: Norio Furukori (Dokkyo Medical University, Department of Psychiatry)

Co-sponsored by Janssen Asia Pacific

[CSS9] The importance of personalizing long-acting injectables and shared decision-making in schizophrenia management

*John M. Kane¹ (1. The Donald and Barbara Zucker School of Medicine)

Sessions

Co-sponsored Symposium / Seminar » Co-sponsored Symposium

Co-sponsored Symposium 1
To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

[CSS1-1] The Significance of Personal Goals in Schizophrenia Treatment: Unmet Needs, Therapeutic Approaches, and Recovery Strategies

[CSS1-2] Optimizing Antipsychotic Treatment for Relapse Prevention and Clinical Recovery in Schizophrenia

[CSS1-3] Psychosocial Treatment with a Focus on Recovery

Co-sponsored Symposium 2
Strategic Approaches to Achieve Recovery

[CSS2-1] Measurement-Based Care in Major Depressive Disorder ~From Remission to Functional Recovery~

[CSS2-2] Challenges to Treatment and Assessment for Achieving Personal Recovery in Patients with Major Depressive Disorder

Co-sponsored Symposium 3
Cognitive Impairment is a Core Feature of Schizophrenia

[CSS3] Cognitive Impairment Is a Core Feature of Schizophrenia

Co-sponsored Symposium 4
Tobacco Harm Reduction - an Update

[CSS4-1] Harm reduction – origins, successes and untapped potential

[CSS4-2] Smoking, safer nicotine products and tobacco harm reduction―around the world in fifteen minutes

[CSS4-3] Japan tops the world in reducing cigarette sales

[CSS4-4] Can e-cigarettes help tobacco cigarette smokers quit? A review of the evidence

[CSS4-5] Decision-making and habit: understanding maladaptive behaviour from basic animal learning research

Co-sponsored Symposium 5
Which interventions are key to change the trajectory of schizophrenia?

[CSS5] The relevance of nonpsychotic symptoms in the management of schizophrenia

Co-sponsored Symposium 6
Measurement Based Care in depression

[CSS6-1] Measurement Based Care in the Treatment of Depression: Psychotherapeutic Approach to Personal Recovery

[CSS6-2] Evaluation of workers with depression at the time of return to work

[CSS6-3] About the real Measurement Based Care using IT devices at psychiatric clinic with using the H-SDS & H-SAS

Co-sponsored Symposium 7
Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

[CSS7-1] Development of an animal model to analyze neural mechanisms of behavioral addiction

[CSS7-2] Analysis of addiction using dopamine-related gene-altered mice

[CSS7-3] Role of basolateral amygdala in formation of preference to nicotine intake behavior

[CSS7-4] Smoking Behaviors: Factors and Mechanisms Mediating Transition to Addiction

[CSS7-5] An attempt to create new diagnostic criteria integrating substance dependence and behavioral addiction

Co-sponsored Symposium 8
The unmet needs of schizophrenia from various stakeholders' point of view

[CSS8-1] 統合失調症当事者へのインタビュー（動画）

[CSS8-2] Issues for the recovery of patients with schizophrenia
~Employment support facility's point of view~

[CSS8-3] 統合失調症当事者のご家族へのインタビュー（動画）

[CSS8-4] After overcoming the acute phase of schizophrenia
~Psychitrist's point of view~

Co-sponsored Symposium 9
The importance of personalizing long-acting injectables and shared decision-making in schizophrenia

[CSS9] The importance of personalizing long-acting injectables and shared decision-making in schizophrenia management

Authentication

Sessions

Co-sponsored Symposium / Seminar » Co-sponsored Symposium

Co-sponsored Symposium 1To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

Co-sponsored Symposium 2Strategic Approaches to Achieve Recovery

Co-sponsored Symposium 3Cognitive Impairment is a Core Feature of Schizophrenia

Co-sponsored Symposium 4Tobacco Harm Reduction - an Update

Co-sponsored Symposium 5Which interventions are key to change the trajectory of schizophrenia?

Co-sponsored Symposium 6Measurement Based Care in depression

Co-sponsored Symposium 7Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

Co-sponsored Symposium 8The unmet needs of schizophrenia from various stakeholders' point of view

Co-sponsored Symposium 9The importance of personalizing long-acting injectables and shared decision-making in schizophrenia

Authentication

Co-sponsored Symposium 1
To Achieve Personal Goals for Patients with Schizophrenia in Patient Centered Care

Co-sponsored Symposium 2
Strategic Approaches to Achieve Recovery

Co-sponsored Symposium 3
Cognitive Impairment is a Core Feature of Schizophrenia

Co-sponsored Symposium 4
Tobacco Harm Reduction - an Update

Co-sponsored Symposium 5
Which interventions are key to change the trajectory of schizophrenia?

Co-sponsored Symposium 6
Measurement Based Care in depression

Co-sponsored Symposium 7
Toward a disease concept integrating substance dependence and behavioral addiction: Consideration of common background from basic and clinical perspectives

Co-sponsored Symposium 8
The unmet needs of schizophrenia from various stakeholders' point of view　

Co-sponsored Symposium 9
The importance of personalizing long-acting injectables and shared decision-making in schizophrenia